NEW YORK (GenomeWeb News) — Protein translation company CODA Genomics today said it has expanded an ongoing collaboration with the Canadian antibody developer Viventia Biotech.
 
Under the terms of the agreement, CODA will apply its protein translational engineering systems to “various antibody projects within Viventia,” CODA said.  
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.